The activation of p53 in tumors: A promising strategy against cancer;Réactivation de p53 dans les tumeurs: Une stratégie antitumorale prometteuse

Medecine/Sciences

Volumn 23, Issue 6-7, 2007, Pages 565-567

  Toledo, Franck ^a   Bluteau, Olivier ^a   Simeonova, Iva ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; DNA; DOXYCYCLINE; ESTROGEN RECEPTOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; SHORT HAIRPIN RNA; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER REGRESSION; CELL CYCLE; DNA REPAIR; GENE MUTATION; HUMAN; LYMPHOMA; MOUSE; NONHUMAN; NOTE; ONCOGENE; ONCOGENE C MYC; SARCOMA; SCID MOUSE; SENESCENCE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 34547133255     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20072367565     Document Type: Note

References (15)

1. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006 ; 6 : 909-23.
2. Vousden KH. Outcomes of p53 activation: spoilt for choice. J Cell Sci 2006 ; 119 : 5015-20.
3. Jia H. Controversial Chinese gene-therapy drug entering unfamiliar territory. Nat Rev Drug Discov 2006 ; 5 : 269-70.
4. Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 2006 ; 13 : 921-6.
5. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007 ; 13 : 23-31.
6. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006 ; 6 : 663-73.
7. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006 ; 444 : 61-6.
8. Toledo F, Krummel KA, Lee CJ, et al. A mouse p53 mutant lacking the proline rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006 ; 9 : 273-85.
9. Francoz S, Froment P, Bogaerts S, et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 2006 ; 103 : 3232-7.
10. Ronai Z. Balancing Mdm2: a Daxx-HAUSP matter. Nat Cell Biol 2006 ; 8 : 790-1.
11. Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006 ; 2 : 202-6.
12. Ringshausen I, O'Shea C, Finch AJ, et al. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006 ; 10 : 501-14.
13. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007 ; 445 : 661-5.
14. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007 ; 445 : 656-60.
15. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006 ; 127 : 1323-34.